Previous cohort studies on individuals with type 2 diabetes have linked treatment with DPP-4 inhibitors (DPP-4i) to various cancers including thyroid tumors, pancreatic cancer, and cholangiocarcinoma [32–34]. The gene discussed is DPP4; the disease is cholangiocarcinoma.